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Summary 
Platelet/endothelial cell adhesion molecule 1 (PECAM-1; CD31) is crucial to the process of leukocyte 
transmigration through intercellular junctions of vascular endothelial cells. A monoclonal antibody 
to PECAM, or recombinant soluble PECAM, blocks transendothelial  migration of monocytes 
by 70-90%. Pretreating either the monocytes or the endothelial  junctions with antibody blocks 
transmigration.  If the endothelium is first activated by cytokines, anti-PECAM antibody or soluble 
recombinant PECAM again block transmigration of both monocytes and neutrophils. Anti-PECAM 
does not block chemotaxis of either cell type. Light and electron microscopy reveal that leukocytes 
blocked in transmigration remain tightly bound to the apical surface of the endothelial cell, precisely 
over the intercellular junction. Thus, the process of leukocyte emigration can be dissected into 
three successive  stages: rolling, mediated by the selectin dass of adhesion molecules; tight adhesion, 
mediated by  the leukocyte  integrins and their  endothelial cell  counter-receptors;  and  now 
transmigration, which, based on these studies, requires PECAM-1. 
"[  ukocytes leave the circulation by binding to the luminal 
surface of the vascular endothelium and then migrating 
between tightly apposed endothelial cells into the body tissues 
(1, 2). This process is constitutive in some situations.  For 
example, monocytes (Mo) 1 exit the circulation at a low fie- 
quency to become tissue macrophages (3). Circulating lym- 
phocytes enter lymph nodes by binding to and migrating across 
the specialized high endothelial venules (HEV) in lymphoid 
tissue (4, 5). This process involves recognition and binding 
of L-selectin to specialized, lymph node-restricted counter- 
receptors on the HEV (6, 7). During the process of inflam- 
mation leukocytes emigrate in large numbers into the inflam- 
matory site by recognizing and binding to cytokine-induced 
cell adhesion molecules (CAMs) on the endothelium (8-10). 
A related process may occur during early atherogenesis when 
Mo (and lymphocytes)  selectively emigrate into the subin- 
tima of affected arteries (11). 
For >100 yr, it has been recognized that within the post- 
capillary venules of inflamed tissue, emigrating leukocytes  leave 
the central stream of the circulation,  roll more slowly along 
the vessel  wall, then stop by adhering tightly to the endothelial 
This paper is dedicated to the loving memory of Zanvil A. Cohn, who 
continues to be an inspiration to generations  of scientists. 
t Abbreviations used in thispaper: EM, electron microscopy; HEC, human 
umbilical vein endothelial  cells; Mo,  monocytes;  M199, medium 199; 
PECAM, platelet/endothelial  cell adhesion molecule. 
surface before squeezing between adjacent endothelial cells 
into the subendothelial tissue (12, 13). Much more recently, 
it has been appreciated that the rolling phenomenon is medi- 
ated by the selectin class of adhesion molecules, while the 
tight adhesion is mediated by the leukocyte/32 integrins and 
their endothelial counter-receptors  (14-16). We now report 
that platelet/endothelial  cell adhesion molecule 1 (PECAM), 
a member of the Ig gene superfamily (17) concentrated in 
the junctions between endothelial cells (18) and expressed on 
the surfaces of Mo and neutrophils (PMN) (19-21), mediates 
adhesive interactions  distal to the adhesion mediated by the 
132 integrins that are crucial for the transendothelial  passage 
of Mo and PMN. Anti-PECAM mAb as well as soluble recom- 
binant PECAM block transmigration of these leukocytes after 
the tight adhesion stage. Thus, leukocyte emigration is ex- 
perimentally dissectable into three steps, each phase medi- 
ated primarily by a different family of adhesion molecules 
(selectins, integrins, Ig superfamily) and their counter-receptors. 
Materials and Methods 
Cells.  Human umbilical  vein endothelial  cells (HEC) were iso- 
lated and cultured on collagen gels as described (18). In some ex- 
periments HEC were  activated  by culturing  in the presence  of  recom- 
binant human TNF-o~ (10 ng/ml in culture medium) for the times 
indicated in the figure legends. TNF-c~ induces the expression of 
endothelial  cell adhesion  moleolles  like E-selectin  (22) and vascular 
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expressed by HEC in this culture system (24). PBMC and PMN 
were isolated from venous blood freshly drawn from healthy volun- 
teers  as described (24). 
Antibodies.  hec7 is a mouse mAb (IgG2a isotype) that binds 
to human PECAM-1 (18). mAb hecl is an IgG2a raised in this 
laboratory from the same original fusion. It recognizes a junction- 
ally  restricted  HEC  integral  membrane  protein  distinct  from 
PECAM.  Clones secreting both mAbs were adapted to growth 
in sernm-free medium (Nutridoma NS; Boehringer Mannheim Bio- 
chemicals,  Indianapolis,  IN), and IgG was selectively precipitated 
by ammonium sulfate. IgG was redissolved,  dialyzed in PBS, and 
sterilized by membrane filtration. Fab and F(ab~  fragments were 
produced by incubating with immobilized papain and pepsin, respec- 
tively (Pierce Chemical Co., Rockford, IL). Undigested antibody 
and Fc fragments were removed by passage over protein A-Sepharose 
(Pharmada Fine Chemicals, Piscataway, NJ). SDS-PAGE performed 
under nonreducing conditions verified  that  the fragments were 
properly cut. SDS-PAGE of overloaded samples demonstrated that 
all IgG and active fragments samples were pure; no extraneous bands 
were present on Coomassie blue stain. 
Other mAbs used in this study, their antigens, and sources were: 
IB4 and 3C10, anti-CD18 and CD14, respectively (from Dr. Samuel 
Wright, The Rockefeller University); W6/32, anti-class I MHC 
(from American Type Culture Collection [ATCC], Rockville, MD); 
9.3C9  (9.3F10),  anti-class  II MHC  (HLA-DR and  HLA-DQ) 
(ATCC HB 180; raised in this department); LB-2, anti-ICAM-1 
(from Dr. Edward Clark, University of Washington, Seattle, WA); 
and 3G8, anti-FeyRIII (from Medarex, West Lebanon, NH). Rabbit 
anti-PECAM serum and preimmune serum were generated against 
PECAM-1 purified from platelets  (25). 
Recombinant Soluble PECAM-I.  A cDNA encoding a form of 
PECAM containing the signal  sequence and five and one-half of 
the six extracellular Ig loops was constructed from an existing full- 
length PECAM cDNA clone in the vector pCDM8  (26).  This 
plasmid was cut with restriction enzymes HindlII and NheI. The 
1,850-bp fragment encoding the external domain of PECAM was 
purified on an agarose gel and ligated to a gel-purified 4,056-bp 
fragment of pcDM8 previously digested with HindlII and XbaI, 
representing the entire vector minus the multiple cloning domain 
from the first XbaI site to the HindlII site. Since XbaI and NheI 
generate the same sticky ends, successfully annealed plasmids con- 
tain the fragment of DNA encoding truncated PECAM inserted 
in the pcDM8 in the proper orientation for expression.  Unique 
BamHI sites in both PECAM and pcDM8 allowed verification of 
this by restriction digest of transformed Escherichia coli MC 1061/p3. 
Purified plasmid was obtained from these cultures on CsC1 gra- 
dients by standard methods (27). COS-1 cells (ATCC) were tran- 
siently transfected by dectroporation of 107 cells in 0.5 ml DME 
with 20 #g plasmid in a gene pulser (Bio-Rad Laboratories,  Rich- 
mond, CA) at 240 mV, 960 #F, 4-mm path length cuvettes. The 
electroporated calls were plated in DME  +  10% FCS overnight, 
passed by trypsinization the next day to help remove dead cells, 
and replated in DME  +  10% FCS. Expression of soluble PECAM 
was checked by immunoprecipitation from conditioned medium 
and immunofluorescence of COS cells on day 3. 
Purification and Characterization of Recombinant Soluble PECAM. 
An immunoaffinity matrix was made by covalently coupling hec7 
mAb to A~-gel 10 (Bio-Rad Laboratories) at a concentration of 
3.8 mg/ml, according to the manufacturer's directions. Conditioned 
medium was collected on day 5 from COS-1 cells transiently trans- 
fected with the construct described above, centrifuged free of cells, 
and passed over a 3-ml column of hec7-A~-gel at 0.3 ml/min. The 
column was washed with 10 vol of SA buffer, 8 vol of detergent 
buffer, and 20 vol of SA buffer (28). Soluble PECAM was eluted 
in 5 ml of 0.05 M diethylamine, pH 11.5, neutralized quickly with 
1 M Tris, pH 8, and dialyzed overnight against PBS. The dial)sate 
was concentrated using a Centricon  |  30 microconcentrator (Ami- 
con Corp., Danvers, MA). Purity was assessed by SDS-PAGE under 
reducing conditions followed by Coomassie blue or silver nitrate 
stain, which showed a single band migrating at 90 kD. The state 
of aggregation was assessed by running the material on a 4-15% 
polyacrylamide gel using nondenaturing buffer strips (Phast-gel  | 
system; Pharmacia Fine Chemicals, Piscataway, NJ) for 154 average 
V-h along with nondeuatured standards  (Pharmacia  Fine Chem- 
icals) according to the manufacturer's directions, followed by silver 
staining.  Protein concentration was determined using the BCA  | 
assay (Pierce  Chemical Co.).  40-60 #g of recombinant soluble 
PECAM was purified from "~350 ml of conditioned medium. 
Metabolic Labelin,~ Immunoprecipitation, and SDS-PAGE.  These 
procedures were performed as previously described (18). Any vari- 
ations  unique to these experiments are described in  the figure 
legends. 
TransendotheliaIMigration Assay.  A variation of the recently pub- 
lished method (24) was used. Briefly, purified PBMC or PMN were 
resuspended to 2 or 1  x  10Vml,  respectively,  in warm medium 
199 (M199) or complete culture medium (20% normal human serum 
in M199) and allowed to settle on confluent monolayers of HEC 
grown in 96-well trays on hydrated collagen gels. In most experi- 
ments anti-PECAM mAb, other anti-PECAM reagents, or con- 
trol mAb were also added at the same time. Transendothelial migra- 
tion was allowed to proceed at 37~  usually for 1 h. The original 
procedure called for inverted centrifugation of the culture in the 
presence of EGTA to separate transmigrated cells from those merely 
bound to the apical HEC surface. To preserve maximum optical 
resolution, this step was replaced by three manual washes in 1 mM 
EGTA, followed by three manual washes in Dulbecco's PBS with 
Ca  2+  and Mg  2+  (DPBS). In  some experiments the monolayers 
were then stained with AgNO3 to visualize the intercellular junc- 
tions (18). The monolayers and remaining leukocytes were then 
fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, 
pH 7.4. Before quantitative analysis the monolayers were stained 
with Wright-Giemsa. 
Three separate methods were used to quantitate transendothelial 
migration. All three gave similar results when used by one or more 
observers to analyze the same experiment. The method described 
first gave somewhat better resolution; hence, most of the quantita- 
tive data presented in this paper are from experiments where this 
method was used. (a) IgG-coated sheep erythrocytes in cold M199 
were added to the transmigration assay at the end of the experi- 
ment, just before the glutaraldehyde fixation step, along with PMA 
(or FMLP for PMN) to fully activate leukocyte Fc3~ receptors (29). 
After incubation for 30 min at 4~  nonbound erythrocytes were 
washed off, and the entire culture system consisting of the HEC 
monolayer, collagen gel, and all associated leukocytes  was trans- 
ferred intact to a glass slide and examined at 500x  by Nomarski 
optics.  Leukocytes were scored as apical if they were in the focal 
plane above the HEC monolayer and bound (rosetted) more than 
three Ig-coated sheep red cells. (b) Each well of the 96-well tray 
was centered in turn over the low-power objective of an inverted 
microscope, and the central field in each well was subsequently ex- 
amined at 400x  using Hoffmann modulation contrast optics (30) 
and the silver-stained HEC junctions to sharply define the apical 
surface of the monolayer. All leukocytes in focus on the apical sur- 
face were scored as nontransmigrated. This included those with 
a small pseudopod extending into the junction. Those leukocytes 
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migrated. (c) The entire culture system was removed from the well 
as for a, and random fields were examined at 500x  under Nomarski 
interference optics, scoring apical and transmigrated leukocytes as 
for b. Data are expressed as percent of total cells viewed that had 
transmigrated; in most samples there were ml00 total leukocytes 
viewed in each field.  The mean and standard deviation of at least 
six replicate cultures are presented. Figures show representative ex- 
periments; all experiments in this paper were repeated at least three, 
and usually more than  six,  times with  similar results. 
Quantitation of Scanning Electron Micrographs.  After the trans- 
migration assay carried out as described above, cultures were fixed 
in 2.5% electron microscopy (EM)-grade glutaraldehyde in 0.1 M 
sodium cacodylate buffer, pH 7.4 (Polysciences,  Warrington, PA). 
The fixed HEC monolayer, associated leukocytes, and collagen gel 
were physically removed from the 96-weU tray and processed for 
scanning EM by critical point drying and gold coating as described 
(31).  For quantitative evaluation, each specimen was centered in 
the beam at low-power ('~,20 x), then Mo were counted in at least 
10 random, nonoverlapping 1,000 x  fields (each field was ~ 10,323 
#m  2)  at  or near  the  center.  Apical Mo  were observed as large, 
mostly spread cells with at least one pseudopod. Cells resembling 
lymphocytes were seen only rarely on the apical surface in the 1- and 
3-h specimens.  At 5 h apically adherent lymphocytes were observed 
at the same density (approximately two per field) in control and 
anti-PECAM-treated  specimens, and were not counted. Data are 
expressed as mean  _+  standard deviation of apical Mo per 1,000x 
field. 
Chemotaxis  Assay.  Hydrated collagen gels identical to those used 
for culture were impregnated with chemoattractant by incubation 
with 200 #1 of chemoattractant solution overnight at 37~  in the 
tissue culture incubator. Control experiments using fluorescently 
labeled IgG demonstrated that equilibration occurred within 6 h 
(tl/2  ffi  45  min) for both accumulation within  and elution from 
the gel. Such gels were washed three times with M199. Leukocytes 
resuspended to 106/ml in M199 plus 0.1% human serum albumin 
with  or without  hec7 IgG or Fab were added to the wells (100 
#l/well),  and migration into the gels was allowed to proceed for 
1 h. Cells that had not entered the gel were removed by inverted 
centrifugation in 20 mM EDTA. The collapsed gels were stained 
with Wright-Giemsa and leukocytes trapped within it were counted 
in the central 200x  field of each well. Data are presented as the 
mean number of leukocytes  _+  standard deviation of six replicate 
wells. 
Results 
Anti-PECAM Antibodies Block Transendothelial  Migration at 
the Intercellular  Junction.  The monocyt~selective in vitro trans- 
migration  assay we have recently reported (24) was used to 
compare transmigration of PBMC treated with anti-PECAM-1 
mAb hec7  (18)  or with  isotype-matched control  mAb.  As 
previously found (24),  all of the Mo in the control samples 
had transmigrated  the HEC monolayer within  40-60  rain, 
while lymphocytes remained unbound or loosely attached and 
were easily removed by the washes in 1 mM EGTA. The Mo 
treated with anti-PECAM mAb also resisted multiple washes 
in  EGTA  and  remained  with  the  HEC  monolayer;  our 
quantitative  assay detected  no differences in the number  of 
111I-labded Mo associated with the monolayer (not shown). 
However,  the  position  of the  Mo  with  respect  to  the  en- 
Figure  1.  Anti-PECAM  antibody blocks transendothelial passage of 
Mo. PBMC were incubated with hec7 anti-PECAM mAb (a) or isotype- 
matched control mAb (b and c), washed free of unbound  antibody, and 
added to confluent HEC monolayers  at 37~  After 1 h, monolayers  were 
washed three times in 1 mM EGTA in HBSS to remove loosely adherent 
leukocytes, stained with silver nitrate and Wright-Giemsa, then examined 
by Normarski interference optics. (a) In the hec7-treated sample, most 
Mo remain tightly attached to the HEC surface in association with the 
intercellular junctions,  which stain black with silver nitrate. These Mo 
are all in a focal plane at the apical surface of the HEC monolayer. In con- 
trast, control Mo have all transmigrated. No Mo are in focus in the plane 
of the apical surface of the monolayer (b), but they can all be visualized 
in various focal planes in the collagen gel below the monolayer (c). White 
arrows point to two such Mo in the corresponding photomicrographs (b 
and c). Bar  ffi  200 #m. 
dothe!ium  was strikingly different.  In contrast  to the con- 
trol Mo,  which  had clearly transmigrated  (Fig.  1,  b and c, 
and reference 24), most of the Mo treated with anti-PECAM 
antibodies remained bound to the apical surface of the HEC 
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cellular junctions  (Fig.  1 a). 
Scanning EM of HEC monolayers exposed to control and 
hec7-treated PBMC for up to 5 h  revealed  dramatic  differ- 
ences. While only rare control Mo were observed on the HEC 
surface, (Fig.  2 a), numerous hec7-treated Mo remained at- 
tached to the apical surface of the monohyer (Fig. 2 b). Higher 
power views revealed that these Mo were well attached and 
mostly spread on the endothelial  surface,  where they were 
associated with insular  junctions between apposing HEC. 
Most appeared to have at least a single pseudopod in the junc- 
tion  (Fig.  2 c). 
Quantitation of the Inhibition of Transraigration.  After 1 h 
at 37~  virtually all of the control Mo were clearly below 
the HEC, whereas <20%  of anti-PECAM-treated  Mo had 
transmigrated (Fig. 3 a). In >50 experiments using the quan- 
titation methods described in Materials and Methods,  hec7 
inhibited Mo transmigration  by 70-90%.  The same results 
were obtained when the transmigration assay was carried out 
in the continuous presence of antibodies (Fig.  3). Since our 
previous results (18, 32) demonstrated that hec7 mAb does 
not disrupt junctions when added to HEC monolayers that 
have already achieved confluence, we presume that in this ex- 
periment, the effect of the mAb continuously present is solely 
on the Mo  (Also see below). 
Anti-PECAM mAb hec7 blocked transmigration  signifi- 
cantly at doses as low as 1 pg/ml, with maximum effect seen 
at "~10 pg/ml,  mAb hec7 at  10-20 pg/ml was as effective 
as a 1:100 dilution of rabbit anti-PECAM serum at blocking 
transmigration  (Fig.  3 b). The effect of hec7 was not medi- 
ated via an effect on the Mo Fc receptor.  Fab fragments of 
hec7 also demonstrated significant inhibitory activity in the 
1-10 #g/ml range (Fig. 3 c). The blockade of transendothelial 
migration  was specific  for PECAM-1.  Several other mAbs 
against Mo surface antigens used at the same concentration 
failed to affect transmigration  (Fig.  3 d).  mAb IB4 against 
CD18, the leukocyte 32 integrin chain, blocked adhesion of 
Mo to the HEC by "~70%, as previously found (24); how- 
ever, those Mo that remained associated with the monolayer 
in  the presence of IB4 transmigrated  apparently  normally. 
Anti-PECAM mAb Does Not Affect Chemotaxis.  Inhibition 
of transmigration  in this  system was not due to the effect 
of the mAb on Mo chemotaxis.  Mo added to gels impreg- 
nated with formylated peptides or with the chemoattractive 
soluble material extractable from the subendothelial collagen 
gels  ("infranate'"  [24])  migrate  into  the  gels  in  a  dose- 
dependent  manner,  similar  to that  seen in a more conven- 
tional Boyden chamber assay (24, 33). Incubation of the PBMC 
with mAb hec7 had no effect on this chemotaxis,  nor did 
it have any effect on the low level of random migration into 
the gel in the absence of chemoattractant  (Fig. 4). Similarly, 
migration  of PMN  to  a  variety  of chemoattractants  was 
unaffected by these concentrations  of hec7 mAb  (Fig.  4). 
The Effect of  Anti-PECAM mAb on Transmigration  Is Long 
Lasting but Reversible.  Inhibition of transmigration  by hec7 
was maintained  in culture for at least 6 h  in the continued 
Figure 2.  hec7  anti-PECAM mAb blocks migration of monocytes through the intercellular  junction. PBMC were incubated for 1 h in complete 
medium containing hec7 or control mAb at 20 #g/ml, then washed in EGTA, fixed, and prepared for scanning EM. Control monolayers (a) were 
virtually devoid of apical Mo, whereas monolayers  exposed  to hecT-treated PBMC were carpeted with Mo (b), most of which appeared to be bound 
over the intercellular  junctions. At higher magnification in tilted specimens (c), some  of the hec7-treated Mo could be seen to be extending pseudopods 
into the junction, although the major portion of the cell remained on the apical surface. 
452  PECAM-1  Is Required for Leukocyte  Transmigration 100 - 
r 
.o 
E 
r  60-  r 
"E  4o- 
to 
20 
C  100 t 
_g  8o1 
"~  60 
e- 
~"  40 
~  20 
T 
Control 
T 
M199  3C10  1  3  10 
i 
hec 7 (p0Vmi) 
~  mAb ptebound  to Mo 
mAb added at to 
hec7 
T 
I 
T 
T 
I 
30  1  10 
hec7 Fab (pg/ml) 
r 
._o 
._ca 
E  r 
t- 
l-- 
$ 
fit. 
d 
c- 
._o 
O~  .m 
E 
t- 
l-- 
2 
~L 
100. 
80" 
60" 
40- 
20- 
100" 
80 
60, 
40, 
J 
t  0 
mAb 
Antigen 
7-  T 
Control  Pre-  hec 7 
anti-  immune  anti- 
CD14  Serum  PECAM 
T 
T 
Rabbit 
anti- 
PECAM 
T  T 
M199  IB4  hec 7  W6/32  9.3C9  3C10  3G8 
CD18  CD31  Class I  Class II  CD14  CD16 
Figure  3.  Anti-PECAM mAb hec7 significantly blocks transendothelial  migration of monocytes. (a) hec7 blocks whether prebound to Mo or added 
at the start  of cocuhure.  PBMC were incubated  with hec7 (anti-PECAM)  or control (anti-CD14)  mAb at 20 #g/ml for 30 min on ice (crosshatched 
bars), washed free of unbound antibody,  and added to HEC monolayers. Alternatively,  equal numbers  of PBMC were added to HEC in the presence 
of the same concentrations  of mAb (open ban). (b) hec7 is as effective as polyclonal anti-PECAM at blocking transmigration.  PBMC were added to 
HEC monolayers in the presence of 20/~g/ml hec7 or anti-CD14,  or a 1:100 dilution of rabbit  anti-PECAM serum  or preimmune serum.  (c) hec7 
Fab as well as IgG significantly blocks transmigration  at low concentrations.  Equal numbers  of PBMC were added to HEC monolayers in M199 or 
M199 supplemented  with either anti-CD14 mAb 3C10 at 30/xg/ml, or hec7 IgG or Fab at the indicated concentrations.  (d) Blockade of transmigration 
is specific for anti-PECAM mAb. Equal numbers  of PBMC were added to HEC monolayers for 1 h in M199 containing the indicated  mAb at 20 
/~g/ml. Only hec7 significantly decreased transmigration  of Mo. In all of the above experiments,  incubation  proceeded at 37~  for 1 h, at which time 
cells were processed as in Materials and Methods,  and the percentage  of the cells remaining  associated with the monolayer  that had  transmigrated 
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presence of the mAb (Fig.  5). Scanning EM of such an ex- 
periment revealed  that control HEC monolayers bore an av- 
erage of 0.4  _+  0.4 apical  Mo per  1,000x  field at all  time 
points, while the monolayers of the hec7-treated  specimen 
bore  15.8  _+  0.5,  16.0  +  6.3,  and 16.0  _+  6.4 apical  Mo 
per 1,000 x  field at 1, 3, and 5 h, respectively. Upon removal 
of hec7 the blockade of transmigration was eliminated,  and 
some Mo transmigration was detected after  30 min.  (This 
contrasts with Fig. 3 a, where the effect of prebound hec7 
lasted for at least  1 h.  The most likely  explanation is that 
in Fig. 5 the Mo were already tightly adherent at the HEC 
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junctions and trying to transmigrate when the block was re- 
moved. They may have been able to overcome a higher con- 
centration of residual hec7 than the resting Mo in Fig.  3 a 
and other similar experiments.) By 2 h after return to con- 
trol medium all Mo had transmigrated (Fig. 5). Thus, anti- 
PECAM mAb is not merely slowing down the transmigra- 
tion process,  and it is not permanently  affecting  the Mo's 
ability to recognize and respond to important signals required 
for transmigration. 
mAb Bound to PECAM in the HEC Junctions Blocks Mo 
Transmigration.  Greater  than 85%  of the PECAM on cul- 140 - 
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nated with (a) M199 or formylnorleucyl-leucyl-phenylalanine  (flqLLP), 
or (b) normal culture medium or infranate from confluent HEC cultures. 
After incubation for I h at 37~  chemotaxis was quantitated as described 
in Materials  and Methods. 
tured HEC is concentrated in the intercellular  junctions (18). 
In this location it is poorly accessible to hec7 mAb applied 
to the apical surface of live, confluent monolayers. Indeed, 
hec7 and several other mAbs recognizing proteins on the HEC 
surface (including ICAM-1) failed to block transmigration 
when HEC were preincubated with these mAbs for 1 h at 
37~  then washed before addition of the PBMC (data not 
shown). 
To study the role of PECAM in the HEC junctions, we 
devised a method to deliver hec7 to that site (see legend to 
Fig. 6). The addition of hec7 Fab fragments to subconfluent 
HEC increased the time required to achieve confluence rela- 
tive to replicate control cultures, as expected (32, 34). How- 
ever, once the monolayer became confluent, it was indistin- 
guishable from control monolayers by phase microscopy (not 
shown). Indirect immunofluorescence microscopy performed 
on live monolayers localized hec7 Fab fragments to the junc- 
tions between adjacent HEC (Fig.  6 a). 
When untreated PBMC or PBMC in the presence of con- 
trol mAb were added to such monolayers (Fig. 7, hec 7 Fab), 
transmigration was blocked. In the experiment shown in Fig. 
7,  as wells as in several similar experiments, the degree of 
inhibition of transmigration was equivalent to what could 
be achieved by hec7 IgG added to the same donor's PBMCs 
on control monolayers (Fig.  7, Control).  The effect of hec7 
Fab was not merely a steric affect due to dogging the inter- 
cellular junction with antibody fragments. As a control for 
this, HEC monolayers were cultured in the presence of Fab 
fragments of mAb hecl, which recognizes a novel integral 
membrane protein of 130 kD that, like PECAM-1, is con- 
centrated in the junctions of HEC, but unlike PECAM, is 
not expressed on leukocytes or platelets. Furthermore, hecl 
is the same isotype as hec7, and Fab fragments of hecl also 
accumulated in HEC intercellular  junctions (Fig. 6 b). How- 
ever, hecl Fab pretreatment had no effect on transmigration 
of untreated Mo (Fig. 7, hec 1 Fab). Of note, blocking PECAM 
on Me and HEC was not additive. No greater inhibition of 
transmigration was achieved when hec7 IgG was added to 
Mo exposed to hec7 Fab pretreated HEC (Fig.  7, hec 7 Fat~ 
filled bar) than was achieved by adding this anti-PECAM re- 
agent to either the Mo (Fig.  7, Control and hec 1 lab, filled 
bars) or the HEC (Fig.  7,  hec 7 lab,  open bar) alone. 
The block of transmigration by hec7 Fab is not due to 
Fab leaking out of the HEC monolayer or subendothelial 
collagen and binding to Mo PECAM. In control experiments 
Fab-pretreated HEC cultures were processed in an identical 
manner to those used in the experiments of Fig. 7. Superna- 
tant was collected from these cultures after 1 h at 37~  and 
used to resuspend freshly isolated PBMC, which were then 
subjected to the transmigration assay. Neither supernate from 
control or hec7 Fab-treated cultures inhibited transmigration 
ofMo (96.8  +  2.6% and97.6 _+ 2.3% transmigration, respec- 
tively). 
Recombinant  Soluble PECAM  Blocks  Transmigration.  A 
454  PECAM-1 Is Required for Leukocyte  Transmigration Figure  6.  hec7 and hecl Fab fragments  bind to their antigens  in the 
intercellular junctions. Normal culture medium supplemented  with Fab 
fragments  of hec7 (anti-PECAM) or control mAb hecl at 20 #g/ml was 
added to subconfluent  HEC and replaced with successive feedings as the 
cells came to confluence over 1 wk. The monolayers were washed exten- 
sively, then incubated successively in FITC-labeled rabbit anti-mouse IgG 
at 1:100 in culture medium (for hec7) or rabbit anti-mouse IgG at 1:400 
followed by rhodamine-conjugated  swine anti-rabbit IgG at  1:100 dilu- 
tion (for hecl) before washing and formalin  fixation.  Phase contrast  mi- 
croscopy revealed typical intact, cobblestone  monolayers (not shown)  in 
both  specimens.  (a)  Fluorescence  image of HEC  allowed  to  come to 
confluence in the presence of hec7 Fab demonstrates  mAb fragments  con- 
centrated in the intercellular junction. (b) Fluorescence image of HEC that 
came to confluence in the presence of hecl Fab shows hecl antigen con- 
centrated  in the intercellular junction, but in a more patchy distribution 
than PECAM. Bar  =  200 #m. 
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soluble recombinant form of PECAM-1  truncated in  the 
middle of the sixth Ig domain significantly inhibits the trans- 
migration of Mo at concentrations as low as 1 #g/ml when 
added to PBMC in our standard assay (Fig.  7, Control and 
hec I, crosshatched  Mrs). Concentrations of 10 #g/ml consis- 
tently inhibited as well as optimal concentrations of hec7 IgG 
in some experiments (not shown), blocking transmigration 
to 10% of control values. The presence of soluble PECAM 
in the incubation medium did not augment the inhibition 
of transmigration effected by hec7 Fab in the HECjunctions 
(Fig.  7,  hec 7 Fab, crosshatched bar). 
Blockade  of transmigration by  these concentrations of 
soluble PECAM predicts a Kd in the range of 10-100 nM. 
This unusually low effective concentration could be explained 
by the fact that the soluble PECAM in these experiments 
was aggregated. Analysis by nondenaturing gds revealed a 
ladder of species in multiples of "~90 kD, with most of the 
material running as apparent hexamers  and octamers (not 
shown). While aggregation would arithmetically decrease 
the apparent molar concentration of this reagent, it would 
exponentially increase the apparent affinity if the monomers 
in the aggregates were still  active. 
Anti.PECAM  mAb  Blocks Transmigration of Mo  across 
Cytokine-activated  HEC Monolayers.  The HEC used in the 
preceding studies did not express cytokine-inducible adhe- 
sion molecules like VCAM-1 or E-selectin, and had basal levels 
of intercellular  adhesion molecule I  (ICAM-1) (24). When 
such monolayers are induced by TNFoe or IL-1  to express 
such adhesion molecules, transmigration of Mo is even more 
rapid than under basal conditions, with 100% of Mo entering 
the subendothelial collagen within 20-30 min (W. A. Muller, 
unpublished data).  However,  hec7 blocked transmigration 
across cytokine-activated HEC monolayers as well as it did 
on resting monolayers (Fig.  8). 
Anti-PECAM  Reagents Block Transmigration of Neutro- 
phils.  Neutrophils also bear  surface PECAM (19-21),  al- 
though hec7 does not bind to the form displayed by PMN 
as well as it binds HEC and Mo (W. A. Muller, unpublished 
observations). Preferential binding of individual anti-PECAM 
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Figure 7.  Transmigration can be blocked by 
anti-PECAM treatment of either Mo or the 
HECjunctions. HEC monolayers were cultured 
under standard conditions  (Control) or in the 
presence of hec7 or hecl Fab as described in 
the legend to Fig. 6. PBMC were resuspended 
in M199 containing control mAb 3C10 (open 
bars) or hec7 (filled bars), both at  20 #g/ml, 
or recombinant  soluble PECAM (sPECAM, 
crosshatched bars) at 1 or 10 #g/ml, and trans- 
migration proceeded  for  1 h.  hec7  blocked 
transmigration  equivalently  whether  it  was 
added to the Mo or the HEC, and there was 
no additional blockade when the two arms were 
combined (hec 7 F~b/fiec7). Soluble recombinant 
PECAM blocked  as well as hec7,  and again, 
was not additive with hec7 Fab bound to the 
HEC (hec 7 Fab/sPECAM). t- 
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Figure  8.  Anti-PECAM mAb hec7 blocks transmigration of mono- 
cytes  across cytokine-activated HEC.  HEC were activated by culturing 
in the presence of 10 ng/ml TNFrv for 3 h to induce VCAM-1 and up- 
regulate ICAM-1. PBMC were added in the presence of hec7 or 3G8 mAb 
at 20/~g/ml, and transmigration was allowed  to proceed for 1 h. 
mAbs to certain types of cells has been previously documented 
(35).  PMN  do  not  migrate readily  across resting  HEC 
monolayers in this system (24), however, they do transmi- 
grate TNFa-activated monolayers readily (W. A. Muller, un- 
published observations). After I h in the presence of control 
antibody,  97%  of the PMNs remaining with the TNFa- 
activated monolayer had migrated beneath it. hec7 blocked 
transmigration by ,v40%, consistent with its relatively weak 
binding to the neutrophil form of this molecule. However, 
a polyclonal rabbit antiserum against PECAM and soluble 
recombinant PECAM at 10 #g/ml blocked transmigration 
down to <20% of control levels (Fig. 9). hec7 had no effect 
on neutrophil movement in chemotaxis assays (Fig. 4). Thus, 
PECAM apparently plays a similar role in the transmigra- 
tion of PMN as it does for Mo. 
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Anti-PECAM reagents block transmigration of neutrophils.  Figure  9. 
HEC monolayers were cultured in the presence of 10 ng/ml TNF-~x for 
2 h to induce the expression of L-selectin as well as VCAM-1 and to en- 
hance ICAM-1 expression.  PMN were resuspended in warm M199 sup- 
plemented with 3C10 or hec7 at 20 Izg/ml, preimmune serum or rabbit 
anti-PECAM serum at 1:100, or recombinant soluble PECAM at 10 #g/ml, 
and added to the activated HEC monolayers for 1 h. 
Discu~ion 
Anti-PECAM Reagents Block Transendothelial Migration. 
Our data demonstrate that PECAM-1 plays a crucial role in 
transendothelial migration of both Mo and PMN across ac- 
tivated and unactivated HEC monolayers. Interfering with 
PECAM function on either the leukocyte or the endothelial 
cell selectively blocks transmigration at an EGTA-resistant 
step after tight adhesion. By our original quantitative trans- 
migration assay, which uses an inverted centrifugation in 
EGTA to strip adherent lenkocytes off the apical surface of 
the monolayer (24), there was no decrease  in the total numbers 
of  leukocytes remaining associated with the monolayers after 
treatment with any anti-PECAM reagent. Thus, it would 
have appeared that anti-PECAM reagents had no effect on 
transmigration. It was only when the position of these leu- 
kocytes with respect to the endothelial monolayer was directly 
visualized by light and s~nning EM that the block of trans- 
migration was so graphically apparent. 
Under control conditions,  virtually 100% of the lenko- 
cytes transmigrate our HEC monolayen within 1 h. In con- 
trast, only 10-30% of the lenkocytes trammigrate in the pres- 
ence of anti-PECAM reagents, and this blockade is maintained 
for at least 6 h in the presence of  anti-PECAM reagents. Since 
all Mo and PMN express relatively high levels of PECAM 
(19), incomplete blockade is not due to absence of PECAM 
from these cells. Neither is it likely to be due to failure of 
our mAb, hec7, to interact with a different PECAM epitope. 
The same statistical results were obtained using a polyclonal 
anti-PECAM antiserum and a form of recombinant soluble 
PECAM comprising almost the entire extracellular domain 
of the molecule.  It is possible that a subset of Mo uses a 
PECAM-independent pathway, or that incomplete block of 
transmigration is merely due to the imperfect nature of our 
in vitro assay. 
The inhibitory effect of hec7 is not due to toxic effects 
on the leukocytes. The mAb does not inhibit chemotaxis of 
Mo or PMN to formylated tripeptides or to "infranate" which 
represents a relevant chemoattractant for transmigration in 
our standard assay (24). Thus, hec7 treatment does not in- 
terfere with either movement of leukocytes per se or with 
activation and function of leukocyte CD11/CD18,  which is 
required for chemotaxis  in these assays and is required for 
binding to HEC in this system (24). Moreover, the effect 
is reversible,  with transmigration of Mo proceeding normally 
once anti-PECAM mAb is withdrawn. 
The epitope of PECAM recognized by mAb hec7 is lo- 
cated in the first and/or second Ig domain, hec7 blocks trans- 
migration, but not heterophilic aggregation, of  PECAM trans- 
fectants, which appears to involve domain six (unpublished 
results).  In preliminary experiments  an anti-PECAM mAb 
against domain six that blocks heterophilic aggregation of 
transfectants did not block transmigration (not shown). Thus, 
there is specificity in the blockade of transmigration by hec7. 
Our results to date with the five and one-half  domain soluble 
PECAM seem to confirm the results with the mAb. We are 
now repeating these initial experiments using more completely 
characterized forms of recombinant soluble PECAM-1. 
456  PECAM-1 Is Required for Leukocyte  Transmigration There is some concern that initial interactions studied in 
vitro in static assay systems may not be relevant to inflamma- 
tion in vivo where leukocyte adhesion to the endothelial sur- 
face must resist the shear forces of the flowing bloodstream. 
Indeed, selectins and integrins function differently under these 
conditions (36, 37). However, we are studying a step in emigra- 
tion distal to the tight integrin-mediated adhesion, and once 
leukocytes are  tightly bound  via  the f12 integrins,  leuko- 
cyte-endothelial adhesion appears  to be refractory to shear 
stress (16). Therefore, our static transmigration system may 
be a relevant model for studying this phase of emigration 
in vitro. 
The Stages of  Leukocyte  Emigration.  The process of  emigra- 
tion can be divided into three stages (reviewed in references 
4 and 8). First, leukocytes leave the circulatory stream, ad- 
hering loosely to the vessd wall as they roll along the en- 
dothdial surface.  This adhesion is believed to be mediated 
by the sdectin class of adhesion molecules and their specific 
carbohydrate ligands. Antibodies against leukocyte L-selectin 
can block  this  rolling  in  vivo  (15)  and purified forms of 
E- and P-selectin can induce this rolling behavior in in vitro 
modds (14,  38).  In the second stage the leukocyte-specific 
(B2) integrins are activated on the rolling cells, resulting in 
cessation of rolling and tight adhesion to the endothelium 
(14,  16).  The activation may be triggered by the selectin- 
mediated binding in an adhesion cascade (39).  In addition, 
integrins can be activated by a variety of relevant chemoat- 
tractants and stimulants (IL-8  [40];  PAF,  C5a,  endotoxin, 
etc. [10, 41]) that they might be exposed to on the surface 
of activated endothdium. Antibodies against CD18,  the fl 
chain of this integrin class, block this tight adhesion (8-10). 
The third step is transendothelial migration: the extravasa- 
tion of the leukocytes between tightly apposed endothdial 
cells. In many in vivo (15, 42) and in vitro systems (24, 43, 
44)  antibodies against leukocyte integrins and/or their en- 
dothelial counter-receptors appear to block transmigration, 
but may, in fact, block the earlier step of tight adhesion to 
endothdium. Our data certainly do not rule out a role for 
CDll/CD18  in the actual transmigration process itself (see 
below); however, they do demonstrate the requirement for 
PECAM-1. 
The ability to arrest transmigration of tightly bound leu- 
kocytes defines the PECAM-1  mediated adhesion as a dis- 
tinct event from the preceding phases of rolling and tight 
adhesion. The process of leukocyte emigration can, for the 
present time, be dissected into three distinct phases (rolling, 
sticking,  transmigration) mediated by the actions of three 
distinct  classes of adhesion molecules (sdectins,  integrins, 
PECAM [Ig superfamily]). This distinction is possible only 
because there are reagents that can block the adhesion mole- 
cules responsible for each step. There may well be other adhe- 
sion molecules awaiting discovery that mediate adhesion events 
in transendothelial migration intermediate or distal to these 
three. 
The Role(s) of PECAM in Transendothelial  Migration.  Pre- 
vious studies on HEC and cell lines transfected with human 
PECAM have demonstrated that PECAM-1 can mediate both 
homophilic (25) and heterophilic (26) adhesion. Since anti- 
PECAM mAb hec7 can block transmigration when bound 
to either the leukocyte or the endothelial cell and these effects 
are not additive, the most straightforward explanation is that 
in this biological system leukocyte PECAM is engaging in 
a homophilic adhesion with PECAM on the HEC junction. 
Moreover, soluble recombinant PECAM blocks transmigra- 
tion as well as anti-PECAM antibody when added to the leu- 
kocytes,  as  expected  if leukocyte PECAM  were  binding 
homophilically to endothelial cell PECAM. However, other 
mechanisms such as bridging of  the two cell types via PECAM 
binding to a soluble molecule, a heterophilic adhesion that 
depended upon functional PECAM on both interacting cells, 
or an indirect signaling role for PECAM that is blocked by 
our mAb are formally possible. 
What is the critical function of PECAM in transmigra- 
tion? The most obvious is that PECAM serves as a direct 
adhesion molecule binding the leukocyte tightly to the HEC 
during its passage  through the junction (Fig.  10 a).  Most 
of the endothelial PECAM is concentrated in the intercel- 
lular junctions, but "~15% is exposed to the apical  surface 
(18). This suggests that an apical-basal  gradient of PECAM 
could exist through the HECjunction. HEC are dearly capable 
of forming and actively maintaining apical-basal  polarity of 
integral membrane proteins (28). An apical-basal gradient of 
adhesion  molecule could  act  similarly to  a  surface-bound 
chemotactic gradient (haptotactic gradient) to produce directed 
migration of leukocytes through the junction  (Fig.  10 b). 
PECAM also could act as an indirect adhesion molecule. Li- 
gation of PECAM on a subset of T cells that express it has 
been shown to  activate/3t  and f12 integrins on those cells 
(45).  Similarly, ligation of PECAM on the Mo and PMN 
Figure 10.  The possible  roles of PECAM-I in transendothelial  migra- 
tion of  leukocytes.  These  schematic  diagrams  depict a Mo or PMN at the 
intercellular  junction of human endothelial  cells. Short black  lines repre- 
sent molecules  of PECAM-1 on the leukocyte  and endothelial  cell that, 
when aligned,  represent  homophilic  adhesion  via PECAM. In b, the den- 
sity of PECAM expressed  in the junction increases  from the luminal to 
the abluminal  surface.  In c, the filled  triangles  represent a ligand  for a leu- 
kocyte  adhesion  molecule  (l,'~), such  as CDll/CD18, that is activated  by 
PECAM-PECAM interactions. See text for details. 
457  Muller  et al. with anti-PECAM F(ab')2 activates CD11/CD18 binding ac- 
tivity (M. E. Berman and W. A. Muller, manuscript in prep- 
aration).  In the confines of the intercellular junction, where 
almost 106 molecules of PECAM are concentrated on each 
HEC (46), homophilic interaction with leukocyte PECAM 
could serve to activate the/32 integrin in such an "adhesion 
cascade" (Fig.  10 c). This mechanism could apply as well if 
there were an apical-basal gradient of PECAM. Hnally, adhe- 
sion of leukocyte PECAM to endothelial  PECAM during 
transmigration may help maintain the tight apposition of these 
cells during this process and help control the effiux of cells 
and soluble molecules during the inflammatory response (Fig. 
10 d).  The hypothesized role(s) of PECAM in transmigra- 
tion are not mutually exclusive and are currently under in- 
vestigation. 
Pathophysiologic  Significance  Mo transmigrate endothelium 
in vivo both constitutively and, in greater numbers, at sites 
of inflammation.  In contrast,  emigration of PMN is essen- 
tially restricted to sites  of acute inflammation.  These cells 
recapitulate this behavior in our in vitro assay (24); Mo trans- 
migrate  across both  resting  and  cytokine-activated  HEC, 
whereas  PMN  transmigrate  only cytokine-activated  HEC 
efficiently.  This assay thus provides a good in vitro model 
of Mo and neutrophil  emigration.  Our  data  suggest  that 
PECAM may play an important role that is common to the 
constitutive emigration  of Mo and the elicited emigration 
of both Mo and FMN. 
With respect to lymphocytes, a subpopulation of circulating 
naive CD8 + T  cells bears PECAM (45), but we do not de- 
tect PECAM on more than a few percent of freshly isolated 
blood lymphocytes (W. A. Muller, unpublished observations). 
Furthermore, we do not detect transmigration of freshly iso- 
lated lymphocytes across our HEC monolayers (24). How- 
ever, lymphocytes clearly enter sites of chronic inflammation 
in vivo.  Since induction  of PECAM has been reported on 
activated T  cells  (19),  it is possible that  when responding 
to  an  antigen  challenge  they do  emigrate  in  a  PECAM- 
dependent manner. This hypothesis is under investigation in 
our laboratory. PECAM-1 (CD31) has been identified on a 
variety of myeloid and lymphoid tumor cell lines (19,  20). 
It is possible that PECAM on these cells aids in their emigra- 
tion  from the bloodstream in the metastatic process. 
Most of the well-known leukocyte-endothelial cell adhe- 
sion molecules have other roles in the immune response. For 
example, ICAM-1 and LFA-1 are important in T cell activa- 
tion (8); CD3 (CDllb/CD18)  is a receptor for a variety of 
ligands, including complement degradation products (47, 48), 
endotoxin  (49),  and bacterial  wall components  (50);  and 
L-selectin is crucial for normal lymphocyte trafficking as well 
as the rolling behavior of PMN (4, 5). At present PECAM 
has no known function in the immune or inflammatory re- 
sponses other than its role in transendothelial  migration.  If 
this proves to be the case, detrimental inflammatory reactions 
could be blocked with  anti-PECAM  reagents without  ad- 
verse side effects on other aspects of the immune response. 
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